Thomas Gad - 06 Nov 2023 Form 4 Insider Report for Y-mAbs Therapeutics, Inc. (YMAB)

Role
Chief Business Officer, Director
Signature
/s/ Thomas Gad
Issuer symbol
YMAB
Transactions as of
06 Nov 2023
Net transactions value
$0
Form type
4
Filing time
08 Nov 2023, 17:19:14 UTC
Previous filing
19 Jan 2023
Next filing
22 Nov 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction YMAB Employee Stock Option (right to buy) Award $0 +75,000 $0.000000 75,000 06 Nov 2023 Common Stock 75,000 $5.75 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Stock options granted to the Reporting Person pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc.
F2 The stock options shall vest and become exercisable as to 25% of the shares subject to the option on November 6, 2024, and thereafter vest and become exercisable as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.